Selected article for: "cancer treatment and combination treatment"

Author: Glantz-Gashai, Yitav; Meirson, Tomer; Reuveni, Eli; Samson, Abraham O
Title: Virtual screening for potential inhibitors of Mcl-1 conformations sampled by normal modes, molecular dynamics, and nuclear magnetic resonance
  • Document date: 2017_6_19
  • ID: 47srfqzl_41
    Snippet: Remarkably, four of these have been associated with the treatment of cancer, namely, nilotinib, cabergoline, miltefosine, and adapalene. Nilotinib is a selective Bcr-Abl tyrosine kinase inhibitor approved for the treatment of chronic myelogenous leukemia. Nilotinib, which shares some structural similarity with ABT-373, is currently undergoing clinical trials in combination with paclitaxel for the treatment of relapsed solid tumors (ClinicalTrials.....
    Document: Remarkably, four of these have been associated with the treatment of cancer, namely, nilotinib, cabergoline, miltefosine, and adapalene. Nilotinib is a selective Bcr-Abl tyrosine kinase inhibitor approved for the treatment of chronic myelogenous leukemia. Nilotinib, which shares some structural similarity with ABT-373, is currently undergoing clinical trials in combination with paclitaxel for the treatment of relapsed solid tumors (ClinicalTrials.gov ID NCT02379416).

    Search related documents:
    Co phrase search for related documents
    • Bcr Abl tyrosine kinase and tyrosine kinase: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • Bcr Abl tyrosine kinase inhibitor and tyrosine kinase: 1, 2, 3
    • cancer treatment and chronic myelogenous leukemia: 1
    • cancer treatment and clinical trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cancer treatment and myelogenous leukemia: 1, 2
    • cancer treatment and paclitaxel combination: 1, 2
    • cancer treatment and solid tumor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • cancer treatment and tyrosine kinase: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • chronic myelogenous leukemia and myelogenous leukemia: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • chronic myelogenous leukemia and tyrosine kinase: 1, 2
    • chronic myelogenous leukemia treatment and myelogenous leukemia: 1, 2, 3
    • clinical trial and myelogenous leukemia: 1
    • clinical trial and paclitaxel combination: 1
    • clinical trial and solid tumor: 1, 2, 3
    • clinical trial and structural similarity: 1, 2, 3
    • clinical trial and tyrosine kinase: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • myelogenous leukemia and tyrosine kinase: 1, 2